Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sophie Ramel

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 18, 2020
Sputum versus nasopharyngeal samples for the molecular diagnosis of respiratory viral infection in cystic fibrosis: A pilot studyEmilie Cardot-Martin, Hélène Le Guillou-Guillemette, Rozenn Le Berre, et al.
ERJ Open Research|March 15, 2021
Chest physiotherapy enhances detection of <i>Pseudomonas aeruginosa</i> in nonexpectorating children with cystic fibrosisChristophe Marguet, Véronique Houdouin, Isabelle Pin, et al.
Journal of Clinical Medicine|November 13, 2020
First Wave of COVID-19 in French Patients with Cystic FibrosisHarriet Corvol, Sandra de Miranda, Lydie Lemonnier, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 6, 2022
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosisClémence Martin, Martine Reynaud-Gaubert, Rebecca Hamidfar, et al.
Annals of the American Thoracic Society|April 5, 2024
Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung DiseasePierre-Régis Burgel, Jean-Louis Paillasseur, Isabelle Durieu, et al.
The Lancet. Respiratory Medicine|September 6, 2025
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studiesPierre-Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, et al.
The Lancet. Respiratory Medicine|August 16, 2024
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world studyPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, et al.
Clinical and Translational Science|May 10, 2025
Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic FibrosisNgoc Hoa Truong, Sihem Benaboud, Naïm Bouazza, et al.
The Journal of Clinical Endocrinology and Metabolism|February 20, 2025
Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosisAlfonso Galderisi, Laurence Weiss, Alix Besançon, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 10, 2014
Central venous thrombosis and thrombophilia in cystic fibrosis: A prospective studyAnne Munck, Ahmed Kheniche, Corinne Alberti, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 18, 2020
Sputum versus nasopharyngeal samples for the molecular diagnosis of respiratory viral infection in cystic fibrosis: A pilot studyEmilie Cardot-Martin, Hélène Le Guillou-Guillemette, Rozenn Le Berre, et al.
ERJ Open Research|March 15, 2021
Chest physiotherapy enhances detection of <i>Pseudomonas aeruginosa</i> in nonexpectorating children with cystic fibrosisChristophe Marguet, Véronique Houdouin, Isabelle Pin, et al.
Journal of Clinical Medicine|November 13, 2020
First Wave of COVID-19 in French Patients with Cystic FibrosisHarriet Corvol, Sandra de Miranda, Lydie Lemonnier, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 6, 2022
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosisClémence Martin, Martine Reynaud-Gaubert, Rebecca Hamidfar, et al.
Annals of the American Thoracic Society|April 5, 2024
Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung DiseasePierre-Régis Burgel, Jean-Louis Paillasseur, Isabelle Durieu, et al.
The Lancet. Respiratory Medicine|September 6, 2025
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studiesPierre-Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, et al.
The Lancet. Respiratory Medicine|August 16, 2024
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world studyPierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, et al.
Clinical and Translational Science|May 10, 2025
Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic FibrosisNgoc Hoa Truong, Sihem Benaboud, Naïm Bouazza, et al.
The Journal of Clinical Endocrinology and Metabolism|February 20, 2025
Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosisAlfonso Galderisi, Laurence Weiss, Alix Besançon, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 10, 2014
Central venous thrombosis and thrombophilia in cystic fibrosis: A prospective studyAnne Munck, Ahmed Kheniche, Corinne Alberti, et al.
Pageof 4